This market research report provides a comprehensive sizing, forecast, and analysis of the global market for biobanking,the storage of biological samples for the future.Includes forecasts through 2015.
REPORT HIGHLIGHTS
- The global biobanking market was $141 billion in 2010 and is projected to increase by 30% between 2010 and 2015, at a compound annual growth rate (CAGR) of 5.4%.
- Private sector biobanks will experience the greatest increase with growth of 64%, at a 5-year CAGR of 10.4% and it is expected to reach $69.6 billion by 2015.
- Population biobanks are projected to increase by 27%, at a CAGR of 5%, as additional population-based biobanks are formed in countries around the world. Disease-based biobanks are projected to increase by 6%, at a 5-year CAGR of 1.2%.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This market research report provides a comprehensive sizing, forecast, and analysis of the global market for “biobanking,” the storage of biological samples for the future.
The report will review global markets for biobank products and will forecast trends and sales in these markets through 2015. The report provides a range of information, from detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends. This information will allow the reader to evaluate and quantify the current market size for specific biobank services within the overall growing biomedical/pharmaceutical technology market.
Forecasts and trends have been developed from a variety of data, including industry sources, company publications, industry benchmarks, and other data sources. Major biobank repositories, technologies, geography, and factors influencing the demand for biobanks will be discussed. Consideration is given to an analysis of government issues versus the biotech/pharmaceutical industry markets.
REASONS FOR DOING THE STUDY
The biobanking market presents the largest of all opportunities in the area of new drug and treatment development for specific diseases. This study investigates one of the most important market drivers in the biotech/pharma area: the introduction to the market of a resource for investigating a variety of combined disease therapies. This is expected to contribute substantially to market growth through the forecast period. This report analyzes emerging biobanking markets, by specific disease segment and specific application. Continued worldwide growth is expected due the growing middle class in emerging countries such as India, China, Brazil, and Russia.
This report addresses the critically important topics of analyzing a changing market dynamic, the emerging players and technologies, strategies for accessing these emerging markets, and measurement and forecast of specific disease segments and geographies to allow for enhanced resource allocation.
SCOPE OF REPORT
Current and projected biobank product forecasts during the forecast period (2010 to 2015) are discussed. Biobanks are playing an important role in new drug development. New products approved by the FDA in 2009 and 2010 are covered, and those products expected to be approved within the forecast period are projected. Due to the timing of the release of this report, the figures for 2010 are estimated, except where actual results have been reported.
The report includes analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market. Profiles of the manufacturers of the leading products are analyzed, and their specific product strategies are outlined. This analysis also includes biotechnology companies that are using biobanks to develop new, novel products. This report looks at companies poised to introduce new products during the forecast period and discusses how these products may change the face of the competitive environment. This competitive environment is examined with a special focus on how developing products and technologies are influencing the current standard of patient care. Detailed profiles of the current market leaders and emerging companies are discussed in detail.
Market figures are based on revenues at the manufacturers’ level, and the base year for analysis and projection is 2010. Inflation is not calculated in the projection figures. Trends are assessed based on a number of parameters, including projected sales for existing products, new product introductions, expanded indications for existing products, and finally, for projected changes in the prevalence, diagnosis, and prescription rates for certain diseases.
Included in this report are an overview and forecast of the biobanking market by product, disease category, geographic region or country, and company for the period of 2009 to 2015. The worldwide market is analyzed and data are provided for each disease subsegment. Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants, and anyone interested in the biobanking market, its products, industry participants, and future.
The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition opportunities, and insights that provide guidance for sales growth and business decisions for a variety of reasons, including the following:
Established companies in the industry will benefit from the contents of this report, including corporate strategy, sales and marketing, business development, and R&D.
Emerging biotechnology players must understand specific opportunities for out-licensing, originating from the differentiation of their biomarker product or technology as compared to leading, competitive, and emerging therapies. In addition, the market forecasts found in this study are supported in detail.
Investment firms evaluating candidates for venture capital or investment in hedge funds will gain insights into the opportunity and risks encountered in the industry, with a product- and company-specific analysis.
Equity analysts are provided with detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this report. In-depth interviews were conducted with leading experts in the field, including company executives, industry analysts, and leading medical practitioners.
The overall biobanking sector comprises a variety of fast growing and independent segments. For completeness, the current and forecasted markets comprise the total market for each respective segment. Within each subsection, there is a detailed forecast of each market driver or relevant area of growth.
The information used in preparing this report was obtained from emerging companies involved the biobanking industry, including their annual reports and 10-Ks. Information was also retrieved from articles published in medical journals such as the American Heart Journal, Circulation, Journal of BioBanks Pharmacology, Lancet, and others, governmental agencies such as the World Health Organization (WHO) and the National Heart, Lung and Blood Institute (NHLBI), and nonprofit organizations such as the American Heart Association. Population estimates are based on those reported by the U.S. Census Bureau’s international database.
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
Table of Contents :
Chapter- 1: INTRODUCTION STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
RELATED BCC REPORTS
Chapter- 2: SUMMARY 3
Table 0 : GLOBAL BIOBANKING REVENUES FORECAST BY SEGMENT, THROUGH 2015
Figure 0 : GLOBAL BIOBANKING REVENUES FORECAST BY SEGMENT, 2009-2015
Chapter- 3: OVERVIEW 14
CURRENT STATE OF THE INDUSTRY
THE PROCESS OF BIOBANKING
HISTORICAL CONTEXT
SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS
MODERN BIOBANKS – PUBLIC SECTOR
BIOBANKING COSTS
DRIVERS OF BIOBANKS EXPANSION
BARRIERS TO BIOBANKS EXPANSION
BIOBANKING TRENDS AND FORECAST
FORECAST FOR BIOBANK INVOLVEMENT IN FUTURE BIOMEDICAL DISCOVERIES
Chapter- 4: OVERVIEW OF BIOBANK APPLICATIONS 17
TYPES OF BIOBANK APPLICATIONS
BIOMARKERS
OPPORTUNITIES IN CANCER
OPPORTUNITIES IN CARDIOVASCULAR DISEASE
OPPORTUNITIES IN NEUROLOGICAL DISEASES
OPPORTUNITIES IN IMMUNOLOGY
OTHER OPPORTUNITIES RESULTING FROM BIOBANKS
Chapter- 5: BIOBANKS WORLDWIDE 14
OVERVIEW
U.S. BIOBANKS
EUROPEAN BIOBANKS
INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD
Chapter- 6: DISEASE-BASED BIOBANKS 10
GROWTH IN DISEASE-BASED BIOBANKS
HEALTHY SAMPLE BIOBANKS
COLLABORATIVE NETWORKS
SEGMENT FORECAST
Chapter- 7: POPULATION-BASED BIOBANKS 11
INTRODUCTION
TYPES OF POPULATION BIOBANKS
FOUNDER POPULATION BIOBANKS
NATIONAL POPULATION BIOBANKS
Chapter- 8: PRIVATE FOR-PROFIT BIOBANKING COMPANIES
CONTRACT BIOBANKING AND SERVICE PROVIDERS
BIOMARKER DISCOVERY COMPANIES
PHARMACEUTICAL COLLECTIONS
RESEARCH COLLABORATIONS
CLINICAL TRIALS
Chapter- 9: THE LIMITATIONS OF BIOBANKS 7
SAMPLE VARIABILITY
SAMPLE QUALITY
EFFORTS TO INCREASE HARMONIZATION
INITIATIVES TO IMPROVE BIOBANKS
Chapter- 10: REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS 16
INTRODUCTION
ROLE OF THE FOOD AND DRUG ADMINISTRATION
CURRENT REGULATORY FRAMEWORK
INFORMED CONSENT
WITHDRAWAL AND OWNERSHIP
CONFIDENTIALITY
COMMERCIALIZATION
FDA GUIDELINES FOR BIOMARKER APPLICATIONS
EUROPEAN MEDICINES AGENCY
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING
ETHICAL CONSIDERATIONS
REGULATORY IMPLICATIONS
Chapter- 11: BIOBANKING MARKETS FORECAST BY SEGMENT AND GEOGRAPHY 2
Table 29 : FORECAST GROWTH FOR BIOBANK-RELATED MARKET, THROUGH 2015
Table 30 : GROWTH IN GLOBAL BIOBANKS BY GEOGRAPHIC REGION, THROUGH 2015
Chapter- 12: DETAILED DESCRIPTIONS OF BIOMARKER APPLICATIONS 46
COLORECTAL CANCER
BREAST CANCER
LUNG CANCER
PROSTATE CANCER
OVARIAN CANCER
MALIGNANT MELANOMA
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
IMMUNOLOGY-AUTOIMMUNE DISEASES
IMMUNOLOGY
Chapter- 13: COMPANY PROFILES 36
ABBOTT LABORATORIES, INC.
AFFYMETRIX, INC.
ASTERAND, PLC
ASTRAZENECA, LTD.
BAYER SCHERING PHARMA AG
BIOCHAIN-GENOMICS
BIOSTORAGE TECHNOLOGIES, INC.
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB CO.
DAIICHI SANKYO CO., LTD.
ELI LILLY AND CO.
EXIQON LIFE SCIENCES
GENTRIS CORP.
GLAXOSMITHKLINE
JOHNSON & JOHNSON, LTD.
MILLENIUM PHARMACEUTICALS
MERCK & CO.
NOVARTIS AG
PFIZER, INC.
ROCHE, LTD.
SANOFI-AVENTIS
SCIPAC
TAKEDA PHARMACEUTICALS, LTD.
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
List of Tables
Summary Table : GLOBAL BIOBANKING REVENUES FORECAST BY SEGMENT, THROUGH 2015
Table 1 : CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970–2009
Table 2 : VALUE OF DNA SAMPLES STORED, THROUGH 2015
Table 3 : NIH-SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000–2008
Table 4 : GLOBAL BIOBANKING MARKET BY APPLICATION, THROUGH 2015
Table 5 : SELECTED U.S. CANCER BIOBANKS
Table 6 : GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE-STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2015
Table 7 : APPLICATIONS OF BIOMARKERS FOR CANCER TREATMENTS
Table 8 : REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL USE: ONCOLOGY
Table 9 : REPRESENTATIVE BIOMARKERS IN U.S. CLINICAL USE: CARDIOVASCULAR
Table 10 : REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL USE: CNS DISEASE
Table 11 : REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL USE: IMMUNOLOGY
Table 12 : TYPES OF BIOBANKS
Table 13 : MAJOR NHLBI COHORT STUDIES
Table 14 : EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS
Table 15 : BIOBANKS LICENSED TO OPERATE IN THE U.K. BY TYPE OF OWNERSHIP, 2008
Table 16 : FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. BY TYPE, 2009/2010
Table 17 : COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES BY SOURCE, 2010
Table 18 : JOINT RESEARCH CENTRE SURVEY OF BIOBANKS IN EU COUNTRIES, 2010
Table 19 : EUROPEAN BIOBANKS BY TYPE OF OWNERSHIP, 2010
Table 20 : ACCESS TO THE EUROPEAN BIOBANK, 2010
Table 21 : U.S. GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY, 1995–2008
Table 22 : SELECTED POPULATION-BASED COHORT BIOBANKS
Table 23 : FOUNDER POPULATION-BASED BIOBANKS
Table 24 : FDA GUIDELINES FOR BIOMARKER APPLICATIONS
Table 25 : ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS SINCE 2005 IN U.S., EUROPE, JAPAN, THROUGH 2015
Table 26 : GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2015
Table 27 : SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY
Table 28 : REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN U.S., EUROPE, JAPAN
Table 29 : FORECAST GROWTH FOR BIOBANK-RELATED MARKET, THROUGH 2015
Table 30 : GROWTH IN GLOBAL BIOBANKS BY GEOGRAPHIC REGION, THROUGH 2015
Table 31 : CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY
Table 32 : REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER
Table 33 : REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER
Table 34 : REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA
Table 35 : REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR
Table 36 : REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE
Table 37 : BIOMARKERS/TESTS FOR OTHER NEUROLOGICAL DISEASES
Table 38 : REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY
Table 39 : ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 40 : ASTERAND’S BIOBANK-RELATED PRODUCTS
Table 41 : ASTRAZENECA’S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 42 : BAYER SCHERING PHARMA CLINICAL TRIAL ON BAY94-9172
Table 43 : BIOCHAIN’S BIOBANK-RELATED PRODUCTS
Table 44 : BIOSTORAGE’S BIOBANK-RELATED PRODUCTS
Table 45 : BRISTOL-MYERS SQUIBB’S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 46 : ELI LILLY’S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 47 : EXIQON’S BIOBANK-RELATED PRODUCTS
Table 48 : GENTRIS’ BIOBANK-RELATED PRODUCTS
Table 49 : GlaxoSmithKline’s REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 50 : MILLENNIUM’S BIOBANK-RELATED PRODUCTS
Table 51 : MERCK’S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 52 : NOVARTIS’ REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 53 : PFIZER’S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 54 : ROCHE’S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 55 : SANOFI-AVENTIS’ REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
Table 56 : SCIPAC’S BIOBANK-RELATED PRODUCTS
List of Figures
Summary Figure : GLOBAL BIOBANKING REVENUES FORECAST BY SEGMENT, 2009-2015
Figure 1 : WORLDWIDE LOCATION OF MAJOR BIOBANKS
0 items in cart
